ARCHIVES

FDA Approves Gleevec For First Line Rx Of CML

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

October 26, 2012

New Treatment Modalities For Endometrial Cancer

March 26, 2004

NCI Separates Carcinogenesis Research Efforts

February 18, 1977

Funding Opportunities

September 13, 2002

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

January 31, 2003

In Brief: Stephen Schimpff Accepts New Position Of Executive Vice President Of Univ. Of Maryland Medical System

October 4, 1985